AUTHORS
Lay She Ng, MBBCh, Wern Lynn Ng, MD2, Annie Curran3, Poornima Ramadas, MD4, Shiva Jashwanth Gaddam, MD5
AFFILIATIONS
1 Indianna University Southwest Internal Medicine Residency, Evansville, Indiana, United States
2 Louisiana State University Health Shreveport, Shreveport, Louisiana, United States
3 Drexel University College of Medicine, philadelphia, Pennsylvania, United States
4 Louisiana State University Health Shreveport, Shreveport, Louisiana, United States
5 Louisiana State University Health Shreveport, Shreveport, Louisiana, United States
ABSTRACT
Background
Daratumumab (Dara)-based regimens have become the standard of care for frontline treatment of newly diagnosed multiple myeloma (NDMM). Randomized clinical trials have demonstrated that quadruplet regimens incorporating Dara with bortezomib (V), lenalidomide (R), and dexamethasone (d) improve clinical outcomes compared with triplet VRd therapy. However, comparative safety data between Dara-based quadruplet (DaraVRd) and triplet (DaraRd) regimens remain limited, particularly in transplant-ineligible patients treated in real-world settings. Understanding the incremental toxicity burden of adding bortezomib to DaraRd is essential for informed treatment selection in this population.
Method
We conducted a retrospective cohort study using the TriNetX real-world data platform, including adult patients with NDMM who are not eligible for transplant. Patients were stratified into the DaraVRd and DaraRd groups. Propensity score matching was performed to balance baseline demographics. The outcomes assessed were mortality, grade 3 ≥ cytopenia, sepsis, peripheral neuropathy, acute renal failure, acute myeloid leukemia/myelodysplastic syndrome (AML/MDS), skin cancer, and urinary tract cancer. Outcomes were compared using event rates, and two-sided p-value <0.05 in the matched cohorts.
Result
After matching, 1321 patients were included in each group, with a mean follow-up of 7.4 months in the DaraVRd group and 9.6 months in the DaraRd group. Mean ages were 70.0 and 70.3 years, respectively, and approximately 53% of patients were male. Most patients were White (60.8% vs 61.8%), followed by Black (19.4% vs18.8%), unknown race (11.5% vs 11.4%), and Asian (3.9% vs 4.2%). The DaraVRd group showed significantly higher rates of ≥ Grade 3 anemia (19.5% vs 14.1%, p = 0.0002) compared to DaraRd group. However, DaraVRd was associated with a lower incidence of skin cancer (2.2% vs 3.6%, p = 0.0362). There was no significant difference observed in mortality (6.2% vs 5.1%, p = 0.2392), ≥ Grade 3 neutropenia
(27.9% vs 27.4%, p = 0.7941), ≥ Grade 3 thrombocytopenia (10.0% vs 9.2%, p = 0.4671), peripheral neuropathy (16.3% vs 18.4%, p = 0.1501), AML/MDS (1.9% vs 1.6%, p = 0.5519), and urinary tract cancer (1.7% vs 1.7%, p = 0.8805).
Conclusion
In this study, DaraVRd and DaraRd demonstrated similar short-term safety profiles, with the exception of a higher incidence of grade ≥3 anemia in the DaraVRd group, suggesting that the addition of bortezomib does not increase the risk of clinically relevant adverse events in real-world practice. Given the limitations of ICD code–based analyses, these findings should be interpreted cautiously and warrant further studies to better clarify the long-term safety of Dara-based quadruplet therapy.
DISCLOSURES
Wern Lynn Ng, MD: No relevant conflicts of interest to declare.